

Antonio J Vallejo-Vaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1415159/publications.pdf>

Version: 2024-02-01

50
papers

2,245
citations

304743

22
h-index

223800

46
g-index

54
all docs

54
docs citations

54
times ranked

3076
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 941-953. | 2.6 | 6 |
| 2 | Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet, The</i> , 2022, 399, 719-728. | 13.7 | 69 |
| 3 | LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9. | 0.8 | 11 |
| 4 | A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 325, 46-56. | 0.8 | 18 |
| 5 | Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725. | 13.7 | 142 |
| 6 | Cerebrovascular Disease and Statins. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 778740. | 2.4 | 8 |
| 7 | Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study. <i>Atherosclerosis</i> , 2021, 338, 39-45. | 0.8 | 2 |
| 8 | Effect of computerised, knowledge-based, clinical decision support systems on patient-reported and clinical outcomes of patients with chronic disease managed in primary care settings: a systematic review. <i>BMJ Open</i> , 2021, 11, e054659. | 1.9 | 18 |
| 9 | Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217. | 6.1 | 169 |
| 10 | Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1742-1759. | 1.6 | 301 |
| 11 | Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1663-1674. | 1.8 | 9 |
| 12 | Triglycerides and residual risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 95-103. | 2.3 | 42 |
| 13 | Familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2020, 31, 111-118. | 2.7 | 11 |
| 14 | Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. <i>Atherosclerosis</i> , 2019, 288, 85-93. | 0.8 | 16 |
| 15 | Premature Morbidity And Mortality Among Diagnosed And Potentially Undiagnosed Familial Hypercholesterolemia Patients In The General Population: An Observational Study Of Over 1.7 Million Health Records. <i>Atherosclerosis</i> , 2019, 287, e15. | 0.8 | 0 |
| 16 | Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. <i>Atherosclerosis</i> , 2019, 288, 194-202. | 0.8 | 56 |
| 17 | Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , 2018, 138, 770-781. | 1.6 | 126 |
| 18 | Epidemiology of familial hypercholesterolaemia: Community and clinical. <i>Atherosclerosis</i> , 2018, 277, 289-297. | 0.8 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255. | 0.8 | 163 |
| 20 | Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. <i>Journal of the American Heart Association</i> , 2018, 7, e009221. | 3.7 | 14 |
| 21 | Response by Vallejo-vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up". <i>Circulation</i> , 2018, 137, 2419-2420. | 1.6 | 1 |
| 22 | Guest Editorial: Reducing Risk in Familial Hypercholesterolaemia and Severe Dyslipidaemia: Novel Drugs Targeting PCSK9. <i>European Cardiology Review</i> , 2018, 13, 7. | 2.2 | 0 |
| 23 | Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). <i>American Journal of Cardiology</i> , 2017, 119, 1352-1358. | 1.6 | 26 |
| 24 | Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome. <i>American Journal of Hypertension</i> , 2017, 30, 673-682. | 2.0 | 28 |
| 25 | LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 55. | 2.8 | 1 |
| 26 | Predictive factors for alirocumab dose increase in patients with heterozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2017, 263, e243. | 0.8 | 0 |
| 27 | Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. <i>Circulation</i> , 2017, 136, 1878-1891. | 1.6 | 144 |
| 28 | Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32. | 1.2 | 90 |
| 29 | Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2016, 116, 162-171. | 3.4 | 32 |
| 30 | Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , 2016, 111, 163-179. | 7.1 | 17 |
| 31 | Promoting high-density lipoprotein function via intravenous infusion: the rebirth of apoA-I Milano?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 30-31. | 3.0 | 6 |
| 32 | Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides – The Case for Soluble ST2. <i>European Cardiology Review</i> , 2015, 10, 37. | 2.2 | 8 |
| 33 | Cholesterol Efflux Capacity as a Novel Biomarker for Incident Cardiovascular Events. <i>Circulation Research</i> , 2015, 116, 1646-1648. | 4.5 | 6 |
| 34 | Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. <i>Atherosclerosis</i> , 2015, 241, 62-68. | 0.8 | 18 |
| 35 | The evolving role of CETP inhibition: beyond HDL cholesterol. <i>Lancet, The</i> , 2015, 386, 412-414. | 13.7 | 11 |
| 36 | Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. <i>Atherosclerosis</i> , 2015, 241, 409-418. | 0.8 | 87 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259. | 0.8 | 148 |
| 38 | Obstructive Sleep Apnoea Syndrome, Endothelial Function and Markers of Endothelialization. Changes after CPAP. <i>PLoS ONE</i> , 2015, 10, e0122091. | 2.5 | 31 |
| 39 | Maternal Body-Mass Index and Cord Blood Circulating Endothelial Colony-Forming Cells. <i>Journal of Pediatrics</i> , 2014, 164, 566-571. | 1.8 | 16 |
| 40 | Obstructive Sleep Apnea Syndrome, Vascular Pathology, Endothelial Function and Endothelial Cells and Circulating Microparticles. <i>Archives of Medical Research</i> , 2013, 44, 409-414. | 3.3 | 31 |
| 41 | Coexistence of two causes of secondary hypertension in a single patient. <i>Revista Clinica Espanola</i> , 2013, 213, e81-e83. | 0.6 | 0 |
| 42 | Role of Circulating Cell-free DNA Levels in Patients With Severe Preeclampsia and HELLP Syndrome. <i>American Journal of Hypertension</i> , 2013, 26, 1377-1380. | 2.0 | 36 |
| 43 | Isolated abducens nerve palsy in preeclampsia and hypertension in pregnancy. <i>Hypertension Research</i> , 2013, 36, 834-835. | 2.7 | 14 |
| 44 | Olive Oil Polyphenols Decrease Blood Pressure and Improve Endothelial Function in Young Women with Mild Hypertension. <i>American Journal of Hypertension</i> , 2012, 25, 1299-304. | 2.0 | 169 |
| 45 | Which parameter is better to define endothelial dysfunction in a test of postocclusive hyperemia measured by Laser-Doppler flowmetry?. <i>Coronary Artery Disease</i> , 2012, 23, 57-61. | 0.7 | 26 |
| 46 | Abnormal levels of antioxidant defenses in a large sample of patients with hypertensive disorders of pregnancy. <i>Hypertension Research</i> , 2012, 35, 274-278. | 2.7 | 12 |
| 47 | The HELLP syndrome (hemolysis, elevated liver enzymes and low platelets): Clinical characteristics and maternal fetal outcome in 172 patients. <i>Pregnancy Hypertension</i> , 2011, 1, 164-169. | 1.4 | 13 |
| 48 | Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome. <i>International Journal of Hypertension</i> , 2011, 2011, 1-8. | 1.3 | 39 |
| 49 | The Postprandial State and its Influence on the Development of Atherosclerosis. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2011, 11, 1-9. | 0.5 | 1 |
| 50 | Differences in the prevalence of metabolic syndrome and levels of C-reactive protein after puerperium in women with hypertensive disorders during pregnancy. <i>Hypertension Research</i> , 2010, 33, 1012-1017. | 2.7 | 10 |